Assess whether a CMC change is a comparability or a new product (cd6859)

Situation

CMC and Development Pathways work in a 505(b)(2) program relying on literature plus a bridging study now turns on a CMC change is because an AdCom briefing document that overstates subgroup findings put disproportionate reporting signal workbook in play. CMC and Development Pathways work in a 505(b)(2) program relying on literature plus a bridging study now turns on a CMC change is because an AdCom briefing document that overstates subgroup findings put disproportionate reporting signal workbook in play; labeling negotiator should say what disproportionate reporting signal workbook proves for Pharma & Life Sciences.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose A CMC change is a comparability / A new product using disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• The population in disproportionate reporting signal workbook is the one an AdCom briefing document that overstates subgroup findings named, so A CMC change is a comparability follows for this CMC and Development Pathways file.
• The population in disproportionate reporting signal workbook is adjacent only to an AdCom briefing document that overstates subgroup findings; A new product is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained an AdCom briefing document that overstates subgroup findings before disproportionate reporting signal workbook arrived; no new CMC and Development Pathways path.
• Provenance on disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings is broken; do not pick A CMC change is a comparability or A new product yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether disproportionate reporting signal workbook supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against an AdCom briefing document that overstates subgroup findings and write the one fact that would move a CMC change is for labeling negotiator.